l General Information |
Product Name | Tranilast |
General description | Tranilast is an antiallergic drug. |
Synonym | 2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino] benzoic acid; Rizaben; SB-252218;3,4-DAA |
Purity | ≥98%(HPLC) | CAS Number | 53902-12-8 |
Formula | C18H17NO5 | Molecular Weight | 327.33 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | Light yellow or light yellow green solid |
Solubility(25℃) | DMSO | ≥50mg/mL |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Tranilast is an anti-asthma drug, which inhibits LTC4 and PGE2 formation in stimulated monocytes, but does not inhibit cyclooxygenase or lipoxygenase activity; inhibits mast cell degranulation; inhibits VEGF-induced angiogenesis in vivo and also inhibits proliferation and tube formation of human endothelial cells in vitro. Tranilast may represent a new class of drugs for therapy to treat ongoing TH1-mediated autoimmune diseases. |
Application | 1. Anti-Allergic Agents 2. Calcium Channel Blockers 3. Anti-Inflammatory Agents, Non-Steroidal 4. Histamine H1 Antagonists 5. Platelet Aggregation Inhibitors |
l Packaging & Storage |
Packaging | 250mg; 1g |
Storage temp. | 0-5℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
